X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (293) 293
Publication (61) 61
Book / eBook (6) 6
Book Chapter (4) 4
Dissertation (2) 2
Book Review (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (176) 176
oncology (112) 112
female (107) 107
male (102) 102
index medicus (85) 85
middle aged (76) 76
adult (71) 71
aged (71) 71
article (54) 54
pharmacokinetics (51) 51
animals (49) 49
neoplasms - drug therapy (48) 48
cancer (44) 44
dose-response relationship, drug (34) 34
antineoplastic agents - pharmacokinetics (33) 33
mice (32) 32
research (31) 31
pharmacology & pharmacy (29) 29
treatment outcome (28) 28
antineoplastic agents - administration & dosage (26) 26
aged, 80 and over (25) 25
area under curve (25) 25
neoplasms - metabolism (24) 24
drug administration schedule (22) 22
child (21) 21
antineoplastic agents - adverse effects (20) 20
adolescent (19) 19
antineoplastic combined chemotherapy protocols - therapeutic use (19) 19
chemotherapy (19) 19
phase-i (19) 19
metabolism (18) 18
sorafenib (18) 18
antineoplastic agents - therapeutic use (17) 17
chemistry, analytical (17) 17
docetaxel (17) 17
niacinamide - analogs & derivatives (17) 17
reproducibility of results (17) 17
administration, oral (16) 16
cells (16) 16
mutation (16) 16
time factors (16) 16
analysis (15) 15
antineoplastic combined chemotherapy protocols - adverse effects (15) 15
biochemical research methods (15) 15
cell line, tumor (15) 15
child, preschool (15) 15
infusions, intravenous (15) 15
taxoids - pharmacokinetics (15) 15
acute myeloid leukemia (14) 14
antineoplastic agents, phytogenic - pharmacokinetics (14) 14
genetics & heredity (14) 14
leukemia (14) 14
leukemia, myeloid, acute - drug therapy (14) 14
mass spectrometry (14) 14
metabolic clearance rate (14) 14
acute myeloid-leukemia (13) 13
antineoplastic combined chemotherapy protocols - pharmacokinetics (13) 13
calibration (13) 13
expression (13) 13
genetic aspects (13) 13
sensitivity and specificity (13) 13
abridged index medicus (12) 12
dosage and administration (12) 12
medicine & public health (12) 12
protein kinase inhibitors - pharmacokinetics (12) 12
australia (11) 11
clinical pharmacokinetics (11) 11
health aspects (11) 11
pharmacology (11) 11
antineoplastic combined chemotherapy protocols - administration & dosage (10) 10
carcinoma (10) 10
care and treatment (10) 10
chromatography, high pressure liquid (10) 10
cytarabine (10) 10
cytosine - analogs & derivatives (10) 10
drug interactions (10) 10
in-vitro (10) 10
inhibition (10) 10
lc/ms/ms (10) 10
mice, knockout (10) 10
paclitaxel (10) 10
paclitaxel - pharmacokinetics (10) 10
pharmacology/toxicology (10) 10
risk factors (10) 10
taxoids - administration & dosage (10) 10
tissue distribution (10) 10
antineoplastic agents - pharmacology (9) 9
biochemistry & molecular biology (9) 9
camptothecin - analogs & derivatives (9) 9
children (9) 9
follow-up studies (9) 9
hematology (9) 9
human plasma (9) 9
maximum tolerated dose (9) 9
medical research (9) 9
metabolites (9) 9
neoplasms - pathology (9) 9
neutropenia - chemically induced (9) 9
phenotype (9) 9
trial (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2009, Volume 15, Issue 19, pp. 6062 - 6069
Journal Article
Leukemia, ISSN 0887-6924, 08/2010, Volume 24, Issue 8, pp. 1437 - 1444
We report the results of a phase I dose escalation trial of the multikinase inhibitor sorafenib in relapsed and refractory acute leukemia patients using an... 
clinical trial | acute myeloid leukemia | signal transduction inhibitors | FLT3 targeted therapy | SOLID TUMORS | FLT3 INHIBITORS | ACUTE MYELOGENOUS LEUKEMIA | DAYS ON/7 DAYS | RAF KINASE | ACUTE MYELOID-LEUKEMIA | ANTITUMOR-ACTIVITY | FACTOR RECEPTOR INHIBITOR | ONCOLOGY | ACUTE LYMPHOBLASTIC-LEUKEMIA | HEMATOLOGY | PHASE-I | Niacinamide - analogs & derivatives | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Recurrence | Humans | Middle Aged | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Pyridines - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Benzenesulfonates - pharmacokinetics | Benzenesulfonates - pharmacology | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Precursor Cell Lymphoblastic Leukemia-Lymphoma - blood | Pyridines - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Leukemia, Myeloid, Acute - blood | Protein Kinase Inhibitors - therapeutic use | Aged | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Acute leukemia | Relapse | Research | Drug therapy | Risk factors | Diseases | Index Medicus | Clinical trial | Tyrosine Kinase inhibitors | Acute Myeloid Leukemia | FLT3
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2011, Volume 29, Issue 24, pp. 3293 - 3300
Journal Article
Nature Communications, ISSN 2041-1723, 12/2019, Volume 10, Issue 1, pp. 244 - 13
Journal Article
PLoS ONE, ISSN 1932-6203, 11/2013, Volume 8, Issue 11, p. e79106
Acute myeloid leukemia (AML) remains a challenging disease to treat and urgently requires new therapies to improve its treatment outcome. In this study, we... 
DNA-DAMAGE RESPONSE | MULTIDISCIPLINARY SCIENCES | ACUTE MYELOGENOUS LEUKEMIA | GENE-EXPRESSION | VALPROIC ACID | ACUTE MYELOID-LEUKEMIA | HISTONE DEACETYLASE INHIBITORS | PHASE-I | HEMATOLOGIC MALIGNANCIES | MYELODYSPLASTIC SYNDROMES | CHEMOTHERAPY SENSITIVITY | Neoplasm Transplantation | Cytarabine - pharmacology | Antibiotics, Antineoplastic - pharmacology | Humans | Leukemia, Myeloid, Acute - metabolism | Daunorubicin - agonists | Child, Preschool | Daunorubicin - pharmacology | Male | Drug Agonism | G2 Phase Cell Cycle Checkpoints - drug effects | Heterografts | U937 Cells | Leukemia, Myeloid, Acute - drug therapy | Antimetabolites, Antineoplastic - pharmacology | Female | Indoles - pharmacology | Protein Kinases - biosynthesis | Child | Hydroxamic Acids - pharmacology | M Phase Cell Cycle Checkpoints - drug effects | Leukemia, Myeloid, Acute - pathology | Gene Expression Regulation, Leukemic - drug effects | Mice, SCID | BRCA1 Protein - biosynthesis | Animals | Checkpoint Kinase 1 | Mice, Inbred NOD | Mice | Rad51 Recombinase - biosynthesis | Daunorubicin | Cytarabine | Research | Drug therapy, Combination | Apoptosis | Pediatrics | Severe combined immunodeficiency | Laboratories | Leukemia | DNA damage | Xenotransplantation | Oncology | Kinases | Cancer therapies | DNA repair | Anticancer properties | Xenografts | Cell cycle | Life sciences | Pharmaceutical sciences | Deoxyribonucleic acid--DNA | Hematology | BRCA1 protein | Myeloid leukemia | CHK1 protein | Breast cancer | Down syndrome | Gene expression | Medicine | Chemotherapy | Molecular modelling | Cell lines | Hypoxia | Diagnostic systems | Mutation | Acute myeloid leukemia | Tumors | Deoxyribonucleic acid | DNA
Journal Article
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 5/2016, Volume 77, Issue 5, pp. 1039 - 1052
This study used uncertainty and sensitivity analysis to evaluate a physiologically based pharmacokinetic (PBPK) model of the complex mechanisms of sorafenib... 
Sensitivity analysis | Medicine & Public Health | Sorafenib | Physiologically based pharmacokinetics | Oncology | Cancer Research | Influx transporters | Pharmacology/Toxicology | Efflux transporters | Niacinamide - analogs & derivatives | Liver - enzymology | Antineoplastic Agents - administration & dosage | Antineoplastic Agents - metabolism | Dose-Response Relationship, Drug | Tissue Distribution | Glucuronosyltransferase - genetics | Cytochrome P-450 CYP3A - genetics | Computer Simulation | Niacinamide - pharmacokinetics | Multidrug Resistance-Associated Proteins - genetics | Antineoplastic Agents - pharmacokinetics | Phenylurea Compounds - metabolism | Phenylurea Compounds - pharmacokinetics | Niacinamide - blood | Niacinamide - metabolism | Liver - metabolism | Phenylurea Compounds - blood | Mice, Knockout | Niacinamide - administration & dosage | Animals | Glucuronosyltransferase - metabolism | Phenylurea Compounds - administration & dosage | Cytochrome P-450 CYP3A - metabolism | Models, Biological | Antineoplastic Agents - blood | Mice | Multidrug Resistance-Associated Proteins - metabolism | Antimitotic agents | Metabolites | Analysis | Liver | Recycling (Waste, etc.) | Cytochrome P-450 | Physiological aspects | Models | Antineoplastic agents | Index Medicus | Efflux Transporters | Physiologically Based Pharmacokinetics | Sensitivity Analysis | Influx Transporters
Journal Article